{"schema_version":"1.0","type":"article","title":"禮來與諾華的大交易，為什麼都看上「怎麼給藥」？","url":"https://drugnews.com.tw/articles/2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026.md","lang":"zh-Hant","date":"2026-09-24","publish_at":"2026-09-24T08:00:00+08:00","updated_at":"2026-09-24","category":"商業分析系列","topic":"商業分析系列","tags":["藥物遞送","BD交易","細胞治療","in vivo CAR-T","皮下注射劑型","Eli Lilly","Kelonia","Novartis","Alteogen","平台型Biotech"],"summary":"禮來押注體內CAR-T製程，諾華取得皮下劑型選擇權。從人體研究、藥物暴露到付款條件，解析兩種遞送平台如何形成產品價值。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"圖1｜兩筆交易分別改變細胞治療製程與生物藥劑型，所取得的權利也不同。","url":"https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026/01_ZH_branded.png"},{"alt":"圖2｜體內CAR-T仍在研究中；示意省略載體進入後的中間分子步驟。","url":"https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026/02_ZH_branded.png"},{"alt":"圖3｜ALT-B4暫時分解皮下透明質酸，協助共同給藥的藥物分散與吸收。","url":"https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026/03_ZH_branded.png"},{"alt":"圖4｜禮來對價分前期約定與或有里程碑；Alteogen各項金額未公開，權利金另計。","url":"https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026/04_ZH_branded.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026/01_ZH_branded.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-24）。禮來與諾華的大交易，為什麼都看上「怎麼給藥」？。https://drugnews.com.tw/articles/2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}